Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.
Melanoma
DRUG: Dabrafenib
Percentage of Participants With Relapse Free Survival, Relapse free survival is defined as the time from surgical resection to the first recurrence or death as assessed by physical examination and radiographic evaluation. All recurrences will be confirmed by biopsy and histologic evaluation., 24 months
Overall Survival, Overall survival is defined as the time from surgical resection to death or last follow-up., 2 years|Number of Participants With Adverse Events, Toxicity will be graded by the NCI Common Toxicity Criteria (CTC) version 4.0 with each cycle of adjuvant dabrafenib., 1 year
In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.